188 related articles for article (PubMed ID: 26004085)
1. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S; Berge EO; Chrisanthar R; Geisler S; Staalesen V; Leirvaag B; Yndestad S; de Faveri E; Karlsen BO; Wedge DC; Akslen LA; Lilleng PK; Løkkevik E; Lundgren S; Østenstad B; Risberg T; Mjaaland I; Aas T; Lønning PE
Mol Oncol; 2015 Oct; 9(8):1553-64. PubMed ID: 26004085
[TBL] [Abstract][Full Text] [Related]
2. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
3. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
4. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
5. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
6. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
7. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
8. The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein.
Derenzini M; Brighenti E; Donati G; Vici M; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Treré D
J Pathol; 2009 Nov; 219(3):373-82. PubMed ID: 19731257
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.
Klajic J; Busato F; Edvardsen H; Touleimat N; Fleischer T; Bukholm I; Børresen-Dale AL; Lønning PE; Tost J; Kristensen VN
Clin Cancer Res; 2014 Dec; 20(24):6357-66. PubMed ID: 25294903
[TBL] [Abstract][Full Text] [Related]
10. Antitumor mechanisms when pRb and p53 are genetically inactivated.
Zhu L; Lu Z; Zhao H
Oncogene; 2015 Aug; 34(35):4547-57. PubMed ID: 25486431
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response.
Lin S; Yu L; Song X; Bi J; Jiang L; Wang Y; He M; Xiao Q; Sun M; Olopade OI; Zhao L; Wei M
Cell Death Dis; 2019 Sep; 10(9):666. PubMed ID: 31511498
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
Staalesen V; Leirvaag B; Lillehaug JR; Lønning PE
Clin Cancer Res; 2004 May; 10(10):3438-43. PubMed ID: 15161699
[TBL] [Abstract][Full Text] [Related]
13. Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas.
Tsoli E; Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Kastrinakis NG; Kokotas S; Kanavaros P; Asimacopoulos P; Bramis J; Kletsas D; Papavassiliou AG; Kittas C
Mol Med; 2001 Jun; 7(6):418-29. PubMed ID: 11474135
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.
Hochhauser D; Schnieders B; Ercikan-Abali E; Gorlick R; Muise-Helmericks R; Li WW; Fan J; Banerjee D; Bertino JR
J Natl Cancer Inst; 1996 Sep; 88(18):1269-75. PubMed ID: 8797766
[TBL] [Abstract][Full Text] [Related]
16. Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation.
Manning AL; Benes C; Dyson NJ
Oncogene; 2014 May; 33(19):2487-94. PubMed ID: 23792446
[TBL] [Abstract][Full Text] [Related]
17. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients.
Aas T; Børresen AL; Geisler S; Smith-Sørensen B; Johnsen H; Varhaug JE; Akslen LA; Lønning PE
Nat Med; 1996 Jul; 2(7):811-4. PubMed ID: 8673929
[TBL] [Abstract][Full Text] [Related]
18. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
19. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
Gorgoulis VG; Koutroumbi EN; Kotsinas A; Zacharatos P; Markopoulos C; Giannikos L; Kyriakou V; Voulgaris Z; Gogas I; Kittas C
Mol Med; 1998 Dec; 4(12):807-22. PubMed ID: 9990866
[TBL] [Abstract][Full Text] [Related]
20. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node.
Lodén M; Stighall M; Nielsen NH; Roos G; Emdin SO; Ostlund H; Landberg G
Oncogene; 2002 Jul; 21(30):4680-90. PubMed ID: 12096344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
